Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors ...

The long-term potential to revolutionize obesity treatment, possibly challenging bariatric surgery, underscores Novo Nordisk's future growth prospects. Novo Nordisk has proven once again that it ...

(Image Credits: PIxabay) Novo Nordisk on Wednesday announced that it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next ...

Shares in Novo Nordisk were up nearly 12% today ... GIP/GLP-1 agonist tirzepatide. Lilly's obesity therapy recently outperformed Wegovy in a head-to-head weight loss study, while CagriSema's ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...

and a head-to-head study pitching CagriSema against Zepbound in obesity. Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...

Novo Nordisk (NVO) CEO Lars Jørgensen isn't too ... "We have maintained our broad access for Wegovy, covering 55 million people with obesity. There were no major changes with opt-ins and opt ...